Verified peer comparison

GILD vs VRTX

Gilead Sciences, Inc. compared with Vertex Pharmaceuticals Incorporated. This page compares both source-verified company profiles and does not introduce an unverified price target.

GILD

Gilead Sciences, Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

VRTX

Vertex Pharmaceuticals Incorporated

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

GILD: Biotechnology

VRTX: Biotechnology

Upside lens

GILD: Biktarvy leadership and Yeztugo adoption can sustain treatment and prevention growth. Trodelvy demand and acquired cell-therapy and antibody-drug-conjugate assets can diversify the portfolio. Livdelzi uptake can add a new growth leg alongside established antiviral franchises.

VRTX: ALYFTREK and expanded eligible populations can sustain the core franchise and reach additional patients. CASGEVY and JOURNAVX adoption can establish meaningful franchises beyond cystic fibrosis. Povetacicept regulatory and late-stage progress can create a fourth major disease-area franchise.

Risk lens

GILD: Heavy reliance on HIV leaves earnings exposed to competition, payer pressure and patent transitions. Large acquisitions and acquired research charges can consume capital without producing approved products. Manufacturing complexity and intense competition can pressure patient access and cell-therapy sales.

VRTX: Cystic fibrosis remains the main revenue source and is exposed to pricing, access and future competition. Gene-editing and pain products face complex patient identification, delivery and reimbursement pathways. Late-stage failures or regulatory delays could materially reduce pipeline diversification value.